FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376640930> ?p ?o ?g. }

• W4376640930 endingPage "175883592311699" @default.
• W4376640930 startingPage "175883592311699" @default.
• W4376640930 abstract "Objective: To investigate the efficacy and safety differences between the cisplatin + paclitaxel (TP) and cisplatin + fluorouracil (PF) regimens in combination with or without immune checkpoint inhibitors (ICIs) in advanced esophageal squamous cell carcinoma (ESCC) first-line treatment and prognostic factors. Methods: We selected the medical records of patients with late stage ESCC admitted to the hospital between 2019 and 2021. Based on the first-line treatment regimen, control groups were divided into chemotherapy plus ICIs ( n = 243) and non-ICIs ( n = 171), 119 (49%) in the TP + ICIs group, 124 (51%) in the PF + ICIs group, 83 (48.5%) in the TP group, and 88 (51.5%) in the PF group in the control group. We analyzed and compared factors related to efficacy, safety, or response to toxicity and prognosis across four subgroups. Results: The overall objective response rate (ORR) and disease control rate (DCR) of the TP plus ICIs group were 42.1% (50/119) and 97.5% (116/119), respectively, which were 6.6% and 7.2% higher than those of the PF plus ICIs group. Patients in the TP combined with ICIs group had higher overall survival (OS) and progression-free survival (PFS) than those in the PF combined with ICIs group [hazard ratio (HR) = 1.702, 95% confidence interval (CI): 0.767–1.499, p = 0.0167 and HR = 1.158, 95% CI: 0.828–1.619, p = 0.0055] ORR and DCR were 15.7% (13/83) and 85.5% (71/83) in the TP chemotherapy alone group, significantly higher than the PF group [13.6% (12/88) and 72.2% (64/88)] ( p < 0.05), OS and PFS were also better in patients treated with TP regimen chemotherapy than PF (HR = 1.173, 95% CI: 0.748–1.839, p = 0.0014 and HR = 0.1.245, 95% CI: 0.711–2.183, p = 0.0061). Furthermore, following the combination of TP and PF diets with ICIs, the OS of the patients was higher than that of the group treated with chemotherapy alone (HR = 0.526, 95% CI: 0.348–0.796, p = 0.0023 and HR = 0.781, 95% CI: 0.0.491–1.244, p < 0.001). Regression analysis showed that the neutrophil-to-lymphocyte ratio (NLR), the control nuclear status score (CONUT), and the systematic immune inflammation index (SII) were independent prognostic factors for the efficacy of immunotherapy ( p < 0.05). The overall incidence of treatment-associated adverse events (TRAEs) was 79.4% (193/243) and 60.8% (104/171) in the experimental and control groups, respectively, and there was no statistically significant difference in TRAEs between TP + ICIs (80.6%) and PF + ICIs (78.2%) (61.4%) and PF groups (60.2%) ( p > 0.05). Overall, 21.0% (51/243) of patients in the experimental group experienced immune-related adverse events (irAEs), and all of these adverse effects were tolerated or remitted following drug treatment without affecting follow-up. Conclusion: The TP regimen was associated with better PFS and OS with or without ICIs. Furthermore, high CONUT scores, high NLR ratios, and high SII were found to be associated with poor prognosis in combination immunotherapy." @default.
• W4376640930 created "2023-05-17" @default.
• W4376640930 creator A5018320592 @default.
• W4376640930 creator A5021234470 @default.
• W4376640930 creator A5036829953 @default.
• W4376640930 creator A5039078092 @default.
• W4376640930 creator A5043945692 @default.
• W4376640930 creator A5068953712 @default.
• W4376640930 creator A5069750524 @default.
• W4376640930 creator A5072492963 @default.
• W4376640930 date "2023-01-01" @default.
• W4376640930 modified "2023-09-26" @default.
• W4376640930 title "Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma" @default.
• W4376640930 cites W2049309222 @default.
• W4376640930 cites W2090822747 @default.
• W4376640930 cites W2131440269 @default.
• W4376640930 cites W2395628172 @default.
• W4376640930 cites W2518018278 @default.
• W4376640930 cites W2580007753 @default.
• W4376640930 cites W2598244115 @default.
• W4376640930 cites W2622199211 @default.
• W4376640930 cites W2749884966 @default.
• W4376640930 cites W2769834914 @default.
• W4376640930 cites W2886081284 @default.
• W4376640930 cites W2900489202 @default.
• W4376640930 cites W2900942065 @default.
• W4376640930 cites W2907395602 @default.
• W4376640930 cites W2924582533 @default.
• W4376640930 cites W2952293896 @default.
• W4376640930 cites W2968972266 @default.
• W4376640930 cites W3037477427 @default.
• W4376640930 cites W3085690887 @default.
• W4376640930 cites W3085737829 @default.
• W4376640930 cites W3092398358 @default.
• W4376640930 cites W3097623339 @default.
• W4376640930 cites W3127371144 @default.
• W4376640930 cites W3131485980 @default.
• W4376640930 cites W3180897560 @default.
• W4376640930 cites W3188668978 @default.
• W4376640930 cites W3189488874 @default.
• W4376640930 cites W3195935456 @default.
• W4376640930 cites W3200109370 @default.
• W4376640930 cites W3210829842 @default.
• W4376640930 cites W4210378853 @default.
• W4376640930 cites W4213020346 @default.
• W4376640930 cites W4213300728 @default.
• W4376640930 cites W4214888158 @default.
• W4376640930 cites W4221045170 @default.
• W4376640930 cites W4225639717 @default.
• W4376640930 cites W4226136872 @default.
• W4376640930 cites W4226155319 @default.
• W4376640930 cites W4281621907 @default.
• W4376640930 cites W4283776951 @default.
• W4376640930 cites W4285005461 @default.
• W4376640930 cites W4288441842 @default.
• W4376640930 cites W4288450894 @default.
• W4376640930 cites W4289782247 @default.
• W4376640930 cites W4293103161 @default.
• W4376640930 cites W4296280974 @default.
• W4376640930 cites W4307327611 @default.
• W4376640930 cites W4312114607 @default.
• W4376640930 cites W4313433838 @default.
• W4376640930 cites W4315498057 @default.
• W4376640930 doi "https://doi.org/10.1177/17588359231169981" @default.
• W4376640930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37188111" @default.
• W4376640930 hasPublicationYear "2023" @default.
• W4376640930 type Work @default.
• W4376640930 citedByCount "0" @default.
• W4376640930 crossrefType "journal-article" @default.
• W4376640930 hasAuthorship W4376640930A5018320592 @default.
• W4376640930 hasAuthorship W4376640930A5021234470 @default.
• W4376640930 hasAuthorship W4376640930A5036829953 @default.
• W4376640930 hasAuthorship W4376640930A5039078092 @default.
• W4376640930 hasAuthorship W4376640930A5043945692 @default.
• W4376640930 hasAuthorship W4376640930A5068953712 @default.
• W4376640930 hasAuthorship W4376640930A5069750524 @default.
• W4376640930 hasAuthorship W4376640930A5072492963 @default.
• W4376640930 hasBestOaLocation W43766409301 @default.
• W4376640930 hasConcept C126322002 @default.
• W4376640930 hasConcept C143998085 @default.
• W4376640930 hasConcept C207103383 @default.
• W4376640930 hasConcept C2776694085 @default.
• W4376640930 hasConcept C2778239845 @default.
• W4376640930 hasConcept C2781413609 @default.
• W4376640930 hasConcept C44249647 @default.
• W4376640930 hasConcept C71924100 @default.
• W4376640930 hasConcept C90924648 @default.
• W4376640930 hasConceptScore W4376640930C126322002 @default.
• W4376640930 hasConceptScore W4376640930C143998085 @default.
• W4376640930 hasConceptScore W4376640930C207103383 @default.
• W4376640930 hasConceptScore W4376640930C2776694085 @default.
• W4376640930 hasConceptScore W4376640930C2778239845 @default.
• W4376640930 hasConceptScore W4376640930C2781413609 @default.
• W4376640930 hasConceptScore W4376640930C44249647 @default.
• W4376640930 hasConceptScore W4376640930C71924100 @default.
• W4376640930 hasConceptScore W4376640930C90924648 @default.
• W4376640930 hasLocation W43766409301 @default.
• W4376640930 hasLocation W43766409302 @default.

• next